THBD and graft versus host disease: There have been reports suggesting that treatment options for TA-TMA include reduction or discontinuation of calcineurin inhibitors that exacerbate vascular endothelial damage, control of infection and graft-vs-host disease [4], and recombinant thrombomodulin [38] and fresh frozen plasma infusion [30].